Vorinostat Capsules
Vorinostat is prescribed for the treatment of treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Vorinostat Dosage forms & Strength :-
Vorinostat 100mg capsule for oral administration only.
Vorinostat Uses :-
Vorinostat is an anti-cancer or chemotherapy drug.. Vorinostat is used for the treatment of :
• Prevent cutaneous manifestations in patients with cutaneous T-
cell lymphoma (CTCL) who have progressive, continues or repeated
disease on or following two systemic therapies.
Vorinostat Dosage :-
Vorinostat is a prescription medicine.
Take Vorinostat properly as your doctor tells you to take it.
The recommended dose of Vorinostat 400 mg orally one time daily with food.
If patient is intolerant to therapy, decrease the dose to Vorinostat 300mg one time orally daily with food. If impotant, reduce the dose further to Vorinostat 300mg one time daily with food for 5 consecutive days each week.
Vorinostat Side-effects :-
Common side effects of Vorinostat:
• Diarrhea,
• Fatigue,
• Nausea,
• Thrombocytopenia,
• Anorexia,
• Dysgeusia.
These are not all the possible side effects of Vorinostat. Consult your doctor and if you have any new or worsening side effects.
Precautions & Warnings :-
• Thromboembolism: Monitor for relevent signs and symptoms of ; pulmonary embolism and deep vein thrombosis.
• Myelosuppression: Thrombocytopenia and anemia can needed dose modification or discontinuation. Monitor blood counts every 2
weeks in the first 2 months of therapy and monthly thereafter.
• Gastrointestinal Toxicity: Nausea, vomiting and diarrhea. patients Can require antiemetics, antidiarrheals, and fluid and electrolyte
replacement to prevent dehydration.
• Hyperglycemia: Monitor blood glucose 2 weeks every during the first 2 months of therapy and monthly afterwards.
• Clinical Chemistry Abnormalities: Measure and correct abnormal electrolytes, creatinine, magnesium and calcium at baseline. Monitor daily 2 weeks during the first 2 months of therapy and at
least monthly during treatment.
• Thrombocytopenia with Concomitant Use of other HDAC
• Inhibitors: critical thrombocytopenia with gastrointestinal bleeding has been described with concomitant use of Vorinostat and other HDAC inhibitors (e.g., valproic acid). Monitor platelet counts more often.
• Embryo-Fetal Toxicity: Fetal harm can happen when administered to
a pregnant woman. Women should be apprised of the potential
harm to the baby.
Vorinostat Brand Name :-
Vorinostat Price :-
MRP ₹ =
Vorinostat Storage :-
Vorinostat : store below 30°C
Classification :-
Drug Name : Vorinostat,
Therapeutics Indiaction : Treatment of treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL).